Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Bone cell-independent benefits of raloxifene on the skeleton: a novel mechanism for improving bone material properties.

Gallant MA, Brown DM, Hammond M, Wallace JM, Du J, Deymier-Black AC, Almer JD, Stock SR, Allen MR, Burr DB.

Bone. 2014 Apr;61:191-200. doi: 10.1016/j.bone.2014.01.009. Epub 2014 Jan 24.

2.

Raloxifene prevents skeletal fragility in adult female Zucker Diabetic Sprague-Dawley rats.

Hill Gallant KM, Gallant MA, Brown DM, Sato AY, Williams JN, Burr DB.

PLoS One. 2014 Sep 22;9(9):e108262. doi: 10.1371/journal.pone.0108262. eCollection 2014.

3.

Raloxifene enhances material-level mechanical properties of femoral cortical and trabecular bone.

Allen MR, Hogan HA, Hobbs WA, Koivuniemi AS, Koivuniemi MC, Burr DB.

Endocrinology. 2007 Aug;148(8):3908-13. Epub 2007 May 3.

PMID:
17478550
4.

Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease.

Newman CL, Creecy A, Granke M, Nyman JS, Tian N, Hammond MA, Wallace JM, Brown DM, Chen N, Moe SM, Allen MR.

Kidney Int. 2016 Jan;89(1):95-104. doi: 10.1038/ki.2015.315. Epub 2016 Jan 4.

5.

Raloxifene reduces skeletal fractures in an animal model of osteogenesis imperfecta.

Berman AG, Wallace JM, Bart ZR, Allen MR.

Matrix Biol. 2016 May-Jul;52-54:19-28. doi: 10.1016/j.matbio.2015.12.008. Epub 2015 Dec 18.

PMID:
26707242
6.

Reference point indentation is insufficient for detecting alterations in traditional mechanical properties of bone under common experimental conditions.

Krege JB, Aref MW, McNerny E, Wallace JM, Organ JM, Allen MR.

Bone. 2016 Jun;87:97-101. doi: 10.1016/j.bone.2016.04.002. Epub 2016 Apr 9.

7.

Incorporation of raloxifene-impregnated allograft around orthopedic titanium implants impairs early fixation but improves new bone formation.

Hermansen LL, Sørensen M, Barckman J, Bechtold JE, Søballe K, Baas J.

Acta Orthop. 2015 Feb;86(1):127-33. doi: 10.3109/17453674.2014.958808. Epub 2014 Sep 1.

8.

Effect of low-dose tacrolimus coadministered with raloxifene on the skeletal system in male rats.

Folwarczna J, Kaczmarczyk-Sedlak I, Pytlik M, Nowińska B, Cegieła U, Sliwiński L, Janiec W, Trzeciak H, Trzeciak HI.

Acta Pol Pharm. 2009 Mar-Apr;66(2):207-12. Erratum in: Acta Pol Pharm. 2009 Jul-Aug;66(4):342.

9.

In vivo reference point indentation reveals positive effects of raloxifene on mechanical properties following 6 months of treatment in skeletally mature beagle dogs.

Aref M, Gallant MA, Organ JM, Wallace JM, Newman CL, Burr DB, Brown DM, Allen MR.

Bone. 2013 Oct;56(2):449-53. doi: 10.1016/j.bone.2013.07.009. Epub 2013 Jul 17.

10.

Structural features underlying raloxifene's biophysical interaction with bone matrix.

Bivi N, Hu H, Chavali B, Chalmers MJ, Reutter CT, Durst GL, Riley A, Sato M, Allen MR, Burr DB, Dodge JA.

Bioorg Med Chem. 2016 Feb 15;24(4):759-67. doi: 10.1016/j.bmc.2015.12.045. Epub 2015 Dec 29. Erratum in: Bioorg Med Chem. 2016 Sep 15;24(18):4516.

11.

In Vivo UTE-MRI Reveals Positive Effects of Raloxifene on Skeletal-Bound Water in Skeletally Mature Beagle Dogs.

Allen MR, Territo PR, Lin C, Persohn S, Jiang L, Riley AA, McCarthy BP, Newman CL, Burr DB, Hutchins GD.

J Bone Miner Res. 2015 Aug;30(8):1441-4. doi: 10.1002/jbmr.2470. Epub 2015 May 21.

12.

Combination treatment with eldecalcitol (ED-71) and raloxifene improves bone mechanical strength by suppressing bone turnover and increasing bone mineral density in ovariectomized rats.

Takeda S, Sakai S, Shiraishi A, Koike N, Mihara M, Endo K.

Bone. 2013 Mar;53(1):167-73. doi: 10.1016/j.bone.2012.12.001. Epub 2012 Dec 8.

PMID:
23232307
13.

Identifying Novel Clinical Surrogates to Assess Human Bone Fracture Toughness.

Granke M, Makowski AJ, Uppuganti S, Does MD, Nyman JS.

J Bone Miner Res. 2015 Jul;30(7):1290-300. doi: 10.1002/jbmr.2452. Epub 2015 Jun 8.

14.

Raloxifene enhances peri-implant bone healing in osteoporotic rats.

Ramalho-Ferreira G, Faverani LP, Prado FB, Garcia IR Jr, Okamoto R.

Int J Oral Maxillofac Surg. 2015 Jun;44(6):798-805. doi: 10.1016/j.ijom.2015.02.018. Epub 2015 Mar 23.

PMID:
25813087
15.

Effects of the combination treatment of raloxifene and alendronate on the biomechanical properties of vertebral bone.

Diab T, Wang J, Reinwald S, Guldberg RE, Burr DB.

J Bone Miner Res. 2011 Feb;26(2):270-6. doi: 10.1002/jbmr.197. Epub 2010 Aug 4.

16.

Fourier transform infrared imaging analysis of cancellous bone in alendronate- and raloxifene-treated osteopenic sheep.

Calton EF, Macleay J, Boskey AL.

Cells Tissues Organs. 2011;194(2-4):302-6. doi: 10.1159/000324236. Epub 2011 May 19.

17.

Alterations in collagen and mineral nanostructure observed in osteoporosis and pharmaceutical treatments using simultaneous small- and wide-angle X-ray scattering.

Acerbo AS, Kwaczala AT, Yang L, Judex S, Miller LM.

Calcif Tissue Int. 2014 Nov;95(5):446-56. doi: 10.1007/s00223-014-9913-0. Epub 2014 Sep 5.

PMID:
25190190
18.

Raloxifene preserves phenytoin and sodium valproate induced bone loss by modulating serum estradiol and TGF-β3 content in bone of female mice.

Anwar MJ, Radhakrishna KV, Sharma A, Vohora D.

Eur J Pharm Sci. 2014 Oct 1;62:219-26. doi: 10.1016/j.ejps.2014.05.018. Epub 2014 May 28.

PMID:
24880111
19.

Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats.

Uyar Y, Baytur Y, Inceboz U, Demir BC, Gumuser G, Ozbilgin K.

Maturitas. 2009 Jul 20;63(3):261-7. doi: 10.1016/j.maturitas.2009.03.018. Epub 2009 Apr 21.

PMID:
19386450
20.

Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats.

Cheng Z, Yao W, Zimmermann EA, Busse C, Ritchie RO, Lane NE.

J Bone Miner Res. 2009 Feb;24(2):209-20. doi: 10.1359/jbmr.81005.

Supplemental Content

Support Center